[Skip to Content]
[Skip to Content Landing]
January 2, 1991

Consensus Reports From the Convinced: Manipulating the Information Transfer Process for Drug Promotion-Reply

Author Affiliations

Sandoz Pharmaceuticals Corp East Hanover, NJ

Sandoz Pharmaceuticals Corp East Hanover, NJ

JAMA. 1991;265(1):30. doi:10.1001/jama.1991.03460010030023

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In Reply.—  We share the concerns of Drs Stern, Arndt, and Baughman about the morality of manipulating information. Indeed, this is not proper. However, there are some additional concerns about who is actually positioned on the "high ground."Drs Stern, Arndt, and Baughman have raised important issues about consensus conferences. The one cited was a European conference of a multidisciplinary nature that included leading experts in the fields of dermatology and nephrology. It was designed to discuss the pros and cons of an experimental treatment for psoriasis. Contrary to the assertion of Drs Stern, Arndt, and Baugham, the conclusion of this conference in fact echoed the recommendations of the 1990 AMA Drug Evaluations; that is, it concluded that the long-term safety of cyclosporine therapy for psoriasis is of primary concern because of the current paucity of data and therefore only dermatologists with expertise in this area should use the drug